139 related articles for article (PubMed ID: 38242546)
1. Clinical impact of CA-125 ELIMination rate constant K (KELIM) on surgical strategy in advanced serous ovarian cancer patients.
Bouvarel B; Colomban O; Frenel JS; Loaec C; Bourgin C; Berton D; Freyer G; You B; Classe JM
Int J Gynecol Cancer; 2024 Apr; 34(4):574-580. PubMed ID: 38242546
[TBL] [Abstract][Full Text] [Related]
2. Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".
van Wagensveld L; Colomban O; van der Aa MA; Freyer G; Sonke GS; Kruitwagen RFPM; You B
J Gynecol Oncol; 2024 May; 35(3):e34. PubMed ID: 38216134
[TBL] [Abstract][Full Text] [Related]
3. CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B; Robelin P; Tod M; Louvet C; Lotz JP; Abadie-Lacourtoisie S; Fabbro M; Desauw C; Bonichon-Lamichhane N; Kurtz JE; Follana P; Leheurteur M; Piano FD; Ferron G; De Rauglaudre G; Ray-Coquard I; Combe P; Chevalier-Place A; Joly F; Leary A; Pujade-Lauraine E; Freyer G; Colomban O
Clin Cancer Res; 2020 Sep; 26(17):4625-4632. PubMed ID: 32209570
[TBL] [Abstract][Full Text] [Related]
4. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
[TBL] [Abstract][Full Text] [Related]
5. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.
Piedimonte S; Kim R; Bernardini MQ; Atenafu EG; Clark M; Lheureux S; May T
Gynecol Oncol; 2022 Dec; 167(3):417-422. PubMed ID: 37191644
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract][Full Text] [Related]
7. KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer.
Kus F; Guven DC; Yildirim HC; Chalabiyev E; Akyildiz A; Tatar OD; Sahin YB; Ileri S; Karaca E; Kertmen N; Arik Z
Biomark Med; 2023 Apr; 17(7):379-389. PubMed ID: 37309756
[TBL] [Abstract][Full Text] [Related]
8. Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial.
Morgan RD; McNeish IA; Cook AD; James EC; Lord R; Dark G; Glasspool RM; Krell J; Parkinson C; Poole CJ; Hall M; Gallardo-Rincón D; Lockley M; Essapen S; Summers J; Anand A; Zachariah A; Williams S; Jones R; Scatchard K; Walther A; Kim JW; Sundar S; Jayson GC; Ledermann JA; Clamp AR
Lancet Oncol; 2021 Feb; 22(2):277-288. PubMed ID: 33357510
[TBL] [Abstract][Full Text] [Related]
9. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
11. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
12. Modeling CA-125 During Neoadjuvant Chemotherapy for Predicting Optimal Cytoreduction and Relapse Risk in Ovarian Cancer.
Ducoulombier S; Golfier F; Colomban O; Benayoun D; Bolze PA; Tod M; You B
Anticancer Res; 2017 Dec; 37(12):6879-6886. PubMed ID: 29187468
[TBL] [Abstract][Full Text] [Related]
13. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Colomban O; Tod M; Leary A; Ray-Coquard I; Lortholary A; Hardy-Bessard AC; Pfisterer J; Du Bois A; Kurzeder C; Burges A; Péron J; Freyer G; You B
Clin Cancer Res; 2019 Sep; 25(17):5342-5350. PubMed ID: 30936122
[TBL] [Abstract][Full Text] [Related]
14. Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
You B; Purdy C; Copeland LJ; Swisher EM; Bookman MA; Fleming G; Coleman R; Randall LM; Tewari KS; Monk BJ; Mannel RS; Walker JL; Cappuccini F; Cohn D; Muzaffar M; Mutch D; Wahner-Hendrickson A; Martin L; Colomban O; Burger RA
J Clin Oncol; 2022 Dec; 40(34):3965-3974. PubMed ID: 36252167
[TBL] [Abstract][Full Text] [Related]
15. Benefit From Fractionated Dose-Dense Chemotherapy in Patients With Poor Prognostic Ovarian Cancer: ICON-8 Trial.
Colomban O; Clamp A; Cook A; McNeish IA; You B
JCO Clin Cancer Inform; 2023 Apr; 7():e2200188. PubMed ID: 37075255
[TBL] [Abstract][Full Text] [Related]
16. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
Corbaux P; You B; Glasspool RM; Yanaihara N; Tinker AV; Lindemann K; Ray-Coquard IL; Mirza MR; Subtil F; Colomban O; Péron J; Karamouza E; McNeish I; Kelly C; Kagimura T; Welch S; Lewsley LA; Paoletti X; Cook A
Eur J Cancer; 2023 Sep; 191():112966. PubMed ID: 37542936
[TBL] [Abstract][Full Text] [Related]
17. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
Gynecol Oncol; 2024 May; 187():92-97. PubMed ID: 38735145
[TBL] [Abstract][Full Text] [Related]
18. Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer.
Saner FAM; Ruggeri G; Siegenthaler F; Wampfler J; Imboden S; Mueller MD
Int J Gynecol Cancer; 2023 Oct; 33(10):1595-1601. PubMed ID: 37567597
[TBL] [Abstract][Full Text] [Related]
19. The Use of CA-125 KELIM to Identify Which Patients Can Achieve Complete Cytoreduction after Neoadjuvant Chemotherapy in High-Grade Serous Advanced Ovarian Cancer.
Zouzoulas D; Tsolakidis D; Tzitzis P; Sofianou I; Chatzistamatiou K; Theodoulidis V; Topalidou M; Timotheadou E; Grimbizis G
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610943
[TBL] [Abstract][Full Text] [Related]
20. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
